Compositions and methods for inhibiting the growth of multi-drug resistant microbes

Patent metadata

Field	Value
Publication number	US-10028933-B2
Application number	US-201615214781-A
Country	US
Kind code	B2
Filing date	Jul 20, 2016
Priority date	Jul 22, 2015
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

Compositions and methods for preventing and treating infection with multi-drug resistant bacteria with AR-13 alone or in combination with antibiotics are provided.

First claim

What is claimed as new and desired to be protected by Letters Patent of the United States is:

1. A method of reducing the load of Burkholderia cenocepacia in a host having cystic fibrosis, comprising:
administering

and an antibiotic to the host wherein the load of the microbes is reduced by about 1000 fold.

2. The method of claim 1 , wherein the microbes are bacteria.

3. The method of claim 2 , wherein the bacteria are multi-drug resistant bacteria.

4. The method of claim 1 , wherein the antibiotic is selected from the group consisting of ceftazidime, ciprofloxacin, gentamicin, and meropenem.

5. The method of claim 1 , wherein AR-13 is administered to the host in an amount sufficient to achieve a blood or tissue concentration of at least about 2.5 μg/ml.

6. The method of claim 1 , wherein the antibiotic is administered to the host in an amount sufficient to achieve a blood or tissue concentration of at least about 5 μg/ml.

7. A method of reducing the titer of Pseudomonas aeruginosa in human neutrophils in a host, comprising:
administering

to the host wherein the titer of the Pseudomonas aeruginosa in human neutrophils is reduced by at least about 4-10 fold.

8. The method of claim 7 , wherein the Pseudomonas aeruginosa is antibiotic-resistant.

9. The method of claim 7 , wherein AR-13 is administered to the host in an amount sufficient to achieve a blood or tissue concentration of at least about 2.5 μM.

10. The method of claim 7 , wherein the antibiotic is administered to the host in an amount sufficient to achieve a blood or tissue concentration of at least about 5 μg/ml.

11. A method of reducing the titer of Burkholderia cenocepacia in human CF macrophages, comprising:
administering

and an antibiotic to the host wherein the titer of the Burkholderia cenocepacia in CF macrophages is reduced by about 1000 fold.

12. The method of claim 11 , wherein the antibiotic is selected from the group consisting of ceftazidime, ciprofloxacin, gentamicin, and meropenem.

13. The method of claim 11 , wherein AR-13 is administered to the host in an amount sufficient to achieve a blood or tissue concentration of at least about 2.5 μM.

14. The method of claim 11 , wherein the antibiotic is administered to the host in an amount sufficient to achieve a peak blood or tissue concentration of at least about 5 μg/ml.

Assignees

• Ohio State Innovation Foundation

Inventors

• Kopp Benjamin
• Schlesinger Larry

Classifications

• A61K31/546

  containing further heterocyclic rings, e.g. cephalothin · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• C07D231/12

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

• A61K31/7036

  having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins · CPC title